Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and Efficacy
Sally C. M. Lau(University Health Network), Adrian G. Sacher(Princess Margaret Cancer Centre), Andrew Hope(University of Toronto), Natasha B. Leighl(Princess Margaret Cancer Centre), B. C. John Cho(Princess Margaret Cancer Centre), Srinivas Raman(Princess Margaret Cancer Centre), Shelley Kuang(Princess Margaret Cancer Centre), Meredith Giuliani(Princess Margaret Cancer Centre), A. Sun(University of Toronto), Deirdre Kelly(University Health Network), Andrea Bezjak(Princess Margaret Cancer Centre), Jessica Weiss(University of Toronto), Ming‐Sound Tsao(Kumamoto University), Aline Fusco Fares(Hospital de Base), Frances A. Shepherd(University Health Network), Sabine Schmid(University of Bern), Geoffrey Liu(Princess Margaret Cancer Centre), Malcolm Ryan(University of Toronto), Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Penelope A. Bradbury(University Health Network), Benjamin H. Lok(University Health Network)
Cited by 11
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k